

Formulation 1a
Formulation 1b
Formulation 2
Formulation 3
Travoprost Release from OTX-TIC
Travoprost Released
110%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
14
28
42
56
70
84
98
112
126
140
Time (Days)

Fig. 1a



P1 Cohort 1 (10261703)
P1 Cohort 2 (D-06061803)
P1 Cohort 3 (050819-201)
P1 Cohort 4 (062619-101)
40C In-vitro Release - OTX-TIC Phase 1
% Travoprost Released
0
10
20
30
40
50
60
70
80
90
100
110
0
10
20
30
40
50
60
70
80
Time (Days)

Fig. 1b



Cohort 1 - 15ug, SAZ, 4A/7A/9A/5.5E
Cohort 2 - 26ug, SAZ, 4A/7A/9A/5.5E
Implant Integrity Rating vs Time (Weeks)
Implant Integrity Rating (1 - 5)
0
2
4
6
8
10
12
14
16
18
20
22
24
0
1
2
3
4
5

Fig. 1c



KFC.1 - KFC
Water [µg]
35
25
15
5
-5
-15
-25
0
10
20
30
40
50
60
t [s]

Fig. 1d



KFC.1 - KFC
Water [µg]
1300
1100
900
700
500
300
100
0
200
400
600
800
1000
t [s]

Fig. 1e



KFC.1 - KFC
Water [µg]
70
50
30
10
-10
-30
0
20
40
60
80
100
120
t [s]

Fig. 1f



Study Eye: OTX-TIC
(~20 estimated subjects)
Non-Study Eye : Topical Travoprost
Medication Washout
Screening
Baseline
Day0
Day1 V3
Day3 V4
Day7 V4.1
Day14 V5
Day28 V6
Day42 V7
Day85 V8
Month 4 V9
Month 5 V10
Month 6 V11
4 Week Follow Up
Month 7-12 V12-V17
Up to 4 week prior to Baseline
Day of Injection
8AM
10AM
4PM
EVALUATION VISITS
FOLLOW UP
*Monthly visits until IOP is within 10% of baseline or until clinical stable
*If needed

Fig. 2




Fig. 3b




Fig. 3a




Fig. 3d




Fig. 3c




Fig. 4a

Fig. 4b




Fig. 4c



n=5 Day1
n=5 Day3
n=4 Day7
n=5 Day14
n=5 Day28
n=5 Day42
n=5 Day85
n=4 Mo 4
n=4 Mo 5
n=3 Mo 6
n=2 Mo 7
n=2 Mo 8
n=2 Mo 9
n=1 Mo 10
n=1 Mo 11
n=1 Mo 12
n=1 Mo 13
n=1 Mo 14
n=1 Mo 15
n=1 Mo 16
n=1 Mo 18
n=1 Mo 20
n=1 Mo 22
-1,40
-1,50
-7,40
-4,60
-8,80
-8,70
-8,00
-9,13
-7,55
-7,00
-6,63
-6,00
-5,20
-5,60
-7,55
-5,8
-5,86
-5,68
-7,44
-4,97
-9,55
-7,05
-6,80
-7,80
-6,55
-6,30
-4,80
-9,80
-8,80
-10,80
-8,8
-12,8
-9,3
-10,8
-8,8
-8,8
-9,8
-6,8
-7,8
-6,8
-6,8
-8,8
-9,3
-6,8
-7,8
-9,3
-5,8
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
-12
-13
SE (OTX-TIC)
NSE (Travatam)

Fig. 5a



n=4 Day 1
n=4 Day 3
n=4 Day 7
n=4 Day 14
n=4 Day 28
n=4 Day 42
n=4 Day 85
n=4 Mo 4
n=4 Mo 5
n=4 Mo 6
n=4 Mo 7
n=3 Mo 8
n=2 Mo 9
-1,88
-2,63
-8,50
-11,63
-8,75
-7,25
-7,38
-6,13
-6,00
-3,63
-4,13
-4,38
-7,00
-5,63
-6,75
-6,50
-6,70
-5,88
-6,43
-6,00
-5,25
-7,75
-6,96
-3,79
-5,88
-5,88
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
-12
-13
SE (OTX-TIC)
NSE (Travatan)

FIG. 5b



n=5 Day 1
n=5 Day 3
n=5 Day 7
n=3* Day 14
n=3* Day 28
n=3 Day 42
n=3 Day 85
n=2 Mo 4
n=2 Mo 5
n=2 Mo 6
N/A** Mo 7
N/A** Mo 8
n=1 Mo 9
-0,70
-0,70
-8,60
-6,60
-5,30
-7,90
-10,17
-7,87
-11,50
-8,03
-7,00
-6,80
-4,7
-7,87
-13,8
-11,2
-10,3
-11,2
-8,2
-9,7
-6,5
-9,7
SE (OTX-TIC)
NSE (Travatan)
1
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
-12
-13
-14
-15

FIG. 5c



n=5
Day 1
n=5
Day 3
n=5
Day 7
n=5
Day 14
n=4
Day 28
n=4
Day 42
n=4
Day 85
n=3
Mo 4
n=1
Mo 5
n=1
Mo 6
0
-0,43
-8,20
-4,2
-10
-7,10
-8,40
-5,8
-8,03
-6,28
-8,15
-6,53
-7,03
-7,40
-8,73
-7,40
-5,90
-4,40
-8,90
-8,90
SE (OTX-TIC)
NSE (Travatan)
1
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
-12
-13
-14

FIG. 5d





FIG. 6



ITEM NO.	DESCRIPTION
1	OTX-TIC (travoprost) Implant
2	Syringe Assembly for OTX-TIC
3	Nipro Ultra-Thin Wall 26G or 27G 1/2" Needle
4	Hamilton Plunger
5	0.009" OD Nitinol Wire
6	Needle Cap
7	OTX-TIC Implant
8	Foil Pouch (2.500" x 9.581")
9	0.009" OD Nitinol Wire, 2.00 cm Length

FIG. 7